----

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION****Washington, D.C.  20549**

**FORM 10–QSB**

| **(Mark One)** |
|----------------|
| x              | **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE   SECURITIES EXCHANGE ACT OF 1934** |
|           |   |
|           | **For the quarterly period ended June   30, 2006** |
|           |   |
| o              | **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE   SECURITIES EXCHANGE ACT OF 1934** |

**Commission file number 0–19671**

| **LASERSIGHT   INCORPORATED**                                   |
|-----------------------------------------------------------------|
|                                                                 |
| *(Name   of Small Business Issuer as specified in its charter)* |

| **Delaware**                                                                         |   | **65–0273162**                        |
|--------------------------------------------------------------------------------------|--------|--------------------------------------------|
|                                                                                      |   |                                            |
| *(State   or other jurisdiction of   incorporation or organization)*                 |   | *(I.R.S.   Employer   Identification No.)* |
|                                                                                 |   |                                       |
| **6848 Stapoint Court, Winter Park,   Florida**                                      |   | **32792**                                  |
|                                                                                      |   |                                            |
| *(Address   of principal executive offices)*                                         |   | *(Zip   Code)*                             |
|                                                                                 |   |                                       |
| **Issuer’s telephone number,   including area code:  (407) 678-9900** |

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. 

| Yes   x | No   o |
|-------------------|------------------|

Indicate by check mark whether theregistrant is a shell company (as defined in Rule 12b-2 of the ExchangeAct).

| Yes   o | No   x |
|-------------------|------------------|

Check whether the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court.

| Yes   x | No   o |
|-------------------|------------------|

Number of shares of common stock outstanding as of August 11, 2006: 9,997,993

Transitional Small Business DisclosureFormat (Check one):  Yes   o  No  x

----

LASERSIGHT INCORPORATED AND SUBSIDIARIES

*Except for the historical information contained herein, the discussion in this report contains forward-looking statements (within the meaning of Section 21E of the Securities Exchange Act of 1934) that involve risks and uncertainties.   LaserSight’s actual results could differ materially from those discussed here.  Factors that could cause or contribute to such differences include, but are not limited to, those discussed in “PART  I – ITEM 1 – DESCRIPTION OF BUSINESS – RISK FACTORS” “PART II – ITEM 6 – MANAGEMENT’S DICUSSION AND ANALYSIS OR PLAN OF OPERATION”  in LaserSight’s Annual Report on Form 10-KSB for the year ended December 31, 2005.  LaserSight undertakes no obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect any future events ordevelopments.*

INDEX

|     |                  |                                                                                                                              | **PAGE** |
|----------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------|----------|
|     |                  |                                                                                                                              |          |
| PART I.  | FINANCIAL INFORMATION |                                                                                                                              |
|     |                  |                                                                                                                              |
|     | Item 1.               | Financial Statements.                                                                                                             |     |
|     |                  |                                                                                                                              |     |
|     |                  | Condensed Consolidated Balance   Sheet as of June 30, 2006 (unaudited)                                                            | 3        |
|     |                  |                                                                                                                              |     |
|     |                  | Condensed Consolidated Statements   of Operations for the Three- and Six-Month Periods Ended June 30, 2006 and   2005 (unaudited) | 4        |
|     |                  |                                                                                                                              |     |
|     |                  | Condensed Consolidated Statements   of Cash Flows for the Six- Month Periods Ended June 30, 2006 and 2005   (unaudited)           | 5        |
|     |                  |                                                                                                                              |     |
|     |                  | Notes to Condensed Consolidated   Financial Statements                                                                            | 6        |
|     |                  |                                                                                                                              |     |
|     | Item 2.               | Management’s Discussion and   Analysis or Plan of Operation.                                                                 | 13       |
|     |                  |                                                                                                                              |     |
|     | Item 3.               | Controls and Procedures.                                                                                                          | 21       |
|     |                  |                                                                                                                              |     |
| PART II. | OTHER INFORMATION     |                                                                                                                              |
|     |                  |                                                                                                                              |
|     | Item 1.               | Legal Proceedings.                                                                                                                | 22       |
|     |                  |                                                                                                                              |     |
|     | Item 2.               | Unregistered Sales of Equity   Securities and Use of Proceeds.                                                                    | 22       |
|     |                  |                                                                                                                              |     |
|     | Item 3.               | Defaults Upon Senior Securities.                                                                                                  | 22       |
|     |                  |                                                                                                                              |     |
|     | Item 4.               | Submission of Matters to a Vote of   Security Holders.                                                                            | 23       |
|     |                  |                                                                                                                              |     |
|     | Item 5.               | Other Information.                                                                                                                | 23       |
|     |                  |                                                                                                                              |     |
|     | Item 6.               | Exhibits.                                                                                                                         | 23       |

Page 2

----

**PART 1 - FINANCIAL INFORMATION**

**LASERSIGHT INCORPORATED AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEET (unaudited)**

|                                                                                                                                |   | **June 30,   2006** |               |
|-------------------------------------------------------------------------------------------------------------------------------------|--------|---------------------|--------------------|
|                                                                                                                                |   |                     |                    |   |
| **ASSETS**                                                                                                                          |   |                |               |   |
| Current assets:                                                                                                                     |   |                |               |   |
| Cash   and cash equivalents                                                                                                         |   | $                   | 322,600            |   |
| Accounts   receivable – trade, net (including receivables from related parties of   $10,657)                                   |   |                | 13,226             |   |
| Inventories,   net                                                                                                                  |   |                | 1,653,331          |   |
| Prepaid   expenses                                                                                                                  |   |                | 56,802             |   |
|                                                                                                                                |   |                     |                    |   |
| Total   Current Assets                                                                                                              |   |                | 2,045,959          |   |
| Property and equipment, net                                                                                                         |   |                | 80,377             |   |
| Patents, net                                                                                                                        |   |                | 399,638            |   |
| Deposits with suppliers                                                                                                             |   |                | 166,075            |   |
| Deferred financing costs,   net                                                                                                     |   |                | 111,337            |   |
|                                                                                                                                |   |                     |                    |   |
| Total   Assets                                                                                                                      |   | $                   | 2,803,386          |   |
|                                                                                                                                |   |                     |                    |   |
| **LIABILITIES AND STOCKHOLDERS’ DEFICIT**                                                                                      |   |                |               |   |
| Current liabilities:                                                                                                                |   |                |               |   |
| Notes   payable                                                                                                                     |   | $                   | 501,744            |   |
| Accounts   payable                                                                                                                  |   |                | 85,035             |   |
| Accrued   expenses                                                                                                                  |   |                | 312,911            |   |
| Accrued   license fees                                                                                                              |   |                | 52,271             |   |
| Accrued   warranty                                                                                                                  |   |                | 89,319             |   |
| Deferred   revenue                                                                                                                  |   |                | 776,364            |   |
|                                                                                                                                |   |                     |                    |   |
| Total   Current Liabilities                                                                                                         |   |                | 1,817,644          |   |
| Note payable related party-   convertible                                                                                           |   |                | 1,000,000          |   |
| Note payable long term   portion                                                                                                    |   |                | 58,930             |   |
| Deferred royalty revenue                                                                                                            |   |                | 3,483,218          |   |
| Commitments and   contingencies Stockholders’ deficit:                                                                         |   |                |               |   |
| Convertible preferred   stock, par value $.001 per share; authorized 10,000,000 shares; none issued                                 |   |                | —   |   |
| Common stock – par value   $.001 per share; authorized 100,000,000 shares; 9,997,195 shares issued and   9,997,193 outstanding |   |                | 9,997              |   |
| Additional paid-in capital                                                                                                          |   |                | 104,738,681        |   |
| Unearned Stock Based   Compensation                                                                                                 |   |                | (69,823            | ) |
| Accumulated deficit                                                                                                                 |   |                | (108,235,261       | ) |
| Less treasury stock, at   cost; 2 common shares                                                                                     |   |                | —   |   |
|                                                                                                                                |   |                     |                    |   |
| Total   Stockholders’ Deficit                                                                                                  |   |                | (3,556,406         | ) |
|                                                                                                                                |   |                     |                    |   |
| Total   Liabilities and Stockholders’ Deficit                                                                                  |   | $                   | 2,803,386          |   |
|                                                                                                                                |   |                     |                    |   |

See accompanying notes to the condensed consolidated financial statements.

Page 3

----

LASERSIGHT INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

|                                                                                                              |   | **Three   Months   Ended   June 30, 2006** |               | **Three Months   Ended   June 30, 2005** |   | **Six Months   Ended   June 30, 2006** |   | **Six Months   Ended   June 30, 2005** |               |
|-------------------------------------------------------------------------------------------------------------------|--------|--------------------------------------------|--------------------|------------------------------------------|--------|----------------------------------------|--------|----------------------------------------|--------------------|
|                                                                                                              |   |                                            |                    |                                     |        |                                        |   |                                        |                    |   |  |  |   |
| Revenues:                                                                                                         |   |                                       |               |                                     |   |                                   |   |                                   |               |   |   |   |   |
| Products                                                                                                          |   | $                                          | 99,321             |                                     | $      | 1,245,168                              |   | $                                      | 521,323            |   | $ | 3,152,558 |   |
| (including   revenues from related parties of $0, $1,143,813, $183,060 in Q1 2006 and $3,029,615,   respectively) |   |                                       |               |                                     |   |                                   |   |                                   |               |   |   |   |   |
| Royalties                                                                                                         |   |                                       | 197,207            |                                     |   | 270,707                                |   |                                   | 391,298            |   |   | 531,212 |   |
|                                                                                                              |   |                                            |                    |                                     |        |                                        |   |                                        |                    |   |  |  |   |
|                                                                                                              |   |                                       | 296,528            |                                     |   | 1,515,875                              |   |                                   | 912,621            |   |   | 3,683,770 |   |
| Cost of revenues:                                                                                                 |   |                                       |               |                                     |   |                                   |   |                                   |               |   |   |   |   |
| Product   cost                                                                                                    |   |                                       | (13,937            | )                                        |   | 680,759                                |   |                                   | 222,575            |   |   | 1,676,040 |   |
|                                                                                                              |   |                                            |                    |                                     |        |                                        |   |                                        |                    |   |  |  |   |
| Gross profit                                                                                                      |   |                                       | 310,465            |                                     |   | 835,116                                |   |                                   | 690,046            |   |   | 2,007,730 |   |
|                                                                                                              |   |                                       |               |                                     |   |                                   |   |                                   |               |   |   |   |   |
| Research and development   and regulatory expenses                                                                |   |                                       | 51,999             |                                     |   | 47,066                                 |   |                                   | 84,000             |   |   | 99,818 |   |
|                                                                                                              |   |                                       |               |                                     |   |                                   |   |                                   |               |   |   |   |   |
| Other general and   administrative expenses                                                                       |   |                                       | 533,954            |                                     |   | 591,477                                |   |                                   | 1,088,284          |   |   | 1,264,594 |   |
| Selling-related expenses                                                                                          |   |                                       | (125,894           | )                                        |   | 14,105                                 |   |                                   | (93,251            | ) |   | 273,497 |   |
| Amortization of intangibles                                                                                       |   |                                       | 8,379              |                                     |   | 8,379                                  |   |                                   | 16,758             |   |   | 16,758 |   |
|                                                                                                              |   |                                            |                    |                                     |        |                                        |   |                                        |                    |   |  |  |   |
|                                                                                                              |   |                                       | 416,439            |                                     |   | 613,961                                |   |                                   | 1,011,791          |   |   | 1,554,849 |   |
|                                                                                                              |   |                                            |                    |                                     |        |                                        |   |                                        |                    |   |  |  |   |
| Income (loss) from operations                                                                                     |   |                                       | (157,973           | )                                        |   | 174,089                                |   |                                   | (405,745           | ) |   | 353,063 |   |
| Other income and expenses:                                                                                        |   |                                       |               |                                     |   |                                   |   |                                   |               |   |   |   |   |
| Interest   and other income                                                                                       |   |                                       | 396                |                                     |   | 1,373                                  |   |                                   | 6,758              |   |   | 2,412 |   |
| Interest   expense                                                                                                |   |                                       | (65,450            | )                                        |   | (82,414                                | )      |                                   | (134,954           | ) |   | (171,292 | ) |
|                                                                                                              |   |                                            |                    |                                     |        |                                        |   |                                        |                    |   |  |  |   |
| Income (loss) before income   tax (expense) benefit                                                               |   |                                       | (223,027           | )                                        |   | 93,048                                 |   |                                   | (533,941           | ) |   | 184,183 |   |
| Income tax   (expense)/benefit                                                                                    |   |                                       | —   |                                     |   | —                       |   |                                   | —   |   |   | —   |   |
|                                                                                                              |   |                                            |                    |                                     |        |                                        |   |                                        |                    |   |  |  |   |
| Net Income(loss)                                                                                                  |   | $                                          | (223,027           | )                                        | $      | 93,048                                 |   | $                                      | (533,941           | ) | $ | 184,183 |   |
|                                                                                                              |   |                                            |                    |                                     |        |                                        |   |                                        |                    |   |  |  |   |
| Income(loss) per common   share                                                                                   |   |                                       |               |                                     |   |                                   |   |                                   |               |   |   |   |   |
| Basic and diluted                                                                                                 |   | $                                          | (0.02              | )                                        | $      | 0.01                                   |   | $                                      | (0.05              | ) | $ | 0.02 |   |
|                                                                                                              |   |                                            |                    |                                     |        |                                        |   |                                        |                    |   |  |  |   |
| Weighted average number of   shares outstanding                                                                   |   |                                       |               |                                     |   |                                   |   |                                   |               |   |   |   |   |
| Basic and diluted                                                                                                 |   |                                       | 9,997,000          |                                     |   | 9,997,000                              |   |                                   | 9,997,000          |   |   | 9,997,000 |   |
|                                                                                                              |   |                                            |                    |                                     |        |                                        |   |                                        |                    |   |  |  |   |

See accompanying notes to the condensed consolidated financial statements.

Page 4

----

LASERSIGHT INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS SIX MONTHS ENDED JUNE 30, 2006 and 2005 (unaudited)

|                                                                                       |   | **June 30,   2006** |               | **June 30,   2005** |   |
|--------------------------------------------------------------------------------------------|--------|---------------------|--------------------|---------------------|--------|
|                                                                                       |   |                     |                    |                |        |  |   |
| Cash flows from operating   activities                                                     |   |                |               |                |   |   |   |
| Net income (loss)                                                                          |   | $                   | (533,941           | )                   | $      | 184,183 |   |
| Adjustments to reconcile   net income (loss) to net cash provided by operating activities: |   |                |               |                |   |   |   |
| Depreciation and amortization                                                              |   |                | 25,155             |                |   | 31,025 |   |
| Amortization of discount on   note payable and deferred financing costs                    |   |                | 56,317             |                |   | 52,316 |   |
| Amortization of stock based   compensation                                                 |   |                | 20,249             |                |   | —   |   |
| Additions to Notes Payable   for fees                                                      |   |                | 25,512             |                |   | —   |   |
| Stock options issued to   employees                                                        |   |                | —   |                |   | 7,800 |   |
| Changes   in assets and liabilities:                                                       |   |                |               |                |   |   |   |
| Accounts   and notes receivable, net                                                       |   |                | 1,433,433          |                |   | (579,905 | ) |
| Inventories                                                                                |   |                | (67,238            | )                   |   | 177,531 |   |
| Accounts   payable                                                                         |   |                | (12,809            | )                   |   | 21,913 |   |
| Accrued   expenses                                                                         |   |                | (203,470           | )                   |   | (30,820 | ) |
| Deferred   revenue                                                                         |   |                | (388,182           | )                   |   | 333,245 |   |
| Other                                                                                      |   |                | (656               | )                   |   | 132,623 |   |
|                                                                                       |   |                     |                    |                |        |  |   |
| Net cash provided by   operating activities                                                |   |                | 354,370            |                |   | 329,911 |   |
| Cash flows from investing   activities                                                     |   |                |               |                |   |   |   |
| Purchases   of property and equipment                                                      |   |                | —   |                |   | (2,573 | ) |
|                                                                                       |   |                     |                    |                |        |  |   |
| Net cash used in investing   activities                                                    |   |                | —   |                |   | (2,573 | ) |
| Cash flows from financing   activities                                                     |   |                |               |                |   |   |   |
| Payments   on debt financing                                                               |   |                | (368,248           | )                   |   | (568,246 | ) |
|                                                                                       |   |                     |                    |                |        |  |   |
| Net cash used in financing   activities                                                    |   |                | (368,248           | )                   |   | (568,246 | ) |
|                                                                                       |   |                     |                    |                |        |  |   |
| Change in cash and cash equivalents                                                        |   |                | (13,878            | )                   |   | (240,908 | ) |
| Cash and cash equivalents,   beginning of period                                           |   |                | 336,478            |                |   | 377,512 |   |
|                                                                                       |   |                     |                    |                |        |  |   |
| Cash and cash equivalents,   end of period                                                 |   | $                   | 322,600            |                | $      | 136,604 |   |
|                                                                                       |   |                     |                    |                |        |  |   |

See accompanying notes to the condensed consolidated financial statements.

Page 5

----

LASERSIGHT INCORPORATED AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Three and Six Month Periods Ended June 30, 2006 and 2005

| NOTE 1 | BASIS OF PRESENTATION                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|   | The accompanying unaudited, condensed consolidated   financial statements of LaserSight Incorporated and subsidiaries   (“LaserSight” or the “Company”) as of June 30, 2006, and for the three- and   six-month periods ended June 30, 2006 and 2005, have been prepared in   accordance with the requirements of the Securities and Exchange Commission   for interim financial information and with the instructions to Form   10-QSB.  Accordingly, they do not   include all of the information and note disclosures required by accounting   principles generally accepted in the United States of America for complete   financial statements.  These condensed   consolidated financial statements should be read in conjunction with the   consolidated financial statements and notes thereto included in LaserSight’s   annual report on Form 10-KSB for the year ended December 31, 2005.  In the opinion of management, the   condensed consolidated financialstatements include all adjustments   necessary, consisting only of normal, recurring adjustments, for a fair   presentation of consolidated financial position and the results of operations   and cash flows for the periods presented.    There are no other components of comprehensive income other than the   Company’s consolidated financial position and the results of operations and   cash flows for the periods presented.    There are no other components of comprehensive income other than the   Company’s consolidated net income (loss) for the three- and six-month periods   ended June 30, 2006 and 2005.  The   results of operations for the three- and six-month periods ended June 30,   2006 and 2005 are not necessarily indicative of the operating results for the   full year. |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|   | The Company’s business is subject to various risks   and uncertainties, which contemplates the realization of assets and the   discharge of liabilities in the normal course of business for the foreseeable   future.  The Company has suffered   recurring losses from operations and has a significant accumulated deficit   that raises substantial doubt about its ability to continue as a going   concern.  Additionally the product   registration of our product in China expired and we may not sell our laser in   China until our registration is approved. Management’s plans in regard to   these matters are described below, see Notes 10 and 11.  The condensed consolidated financial   statements do not include any adjustments that might result from the outcome   of this uncertainty.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|   | The loss of Shenzhen New Industries Medical   Development Co., Ltd. (“NIMD”), a related party, as a customer or the   non-payment or slow payment of monies owed to the Company, compounded by the   fact that we can not sell our product in China until product registration is   approved, would have a significant adverse effect on the Company’s ability to   continue as a going concern.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| NOTE 2 | CRITICAL ACCOUNTING   POLICIES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|   | The Company’s condensed   consolidated financial statements have been prepared in accordance with   accounting principles generally accepted in the United States of America.   Preparation of these statements requires management to make judgments and   estimates that affect the amounts and disclosures in the financial   statements.  Actual results could   differ from these estimates. Some accounting policies have a significant   impact on amounts reported in these financial statements. A summary of significant   accounting policies and a description of accounting policies that are   considered critical may be found in our Annual Report on Form 10-KSB, for the   year ended December 31, 2005, in the Critical Accounting Policies and   Estimates section of “Part II - Item 6. - Management’s Discussion and   Analysis or Plan of Operation.”                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

Page 6

----

|   | Product cost – Product costs consists of the costs   of all machines and parts sold including refurbished laser heads. When the   Company sells refurbished laser heads it offers a discount on the sales price   if the used laser head is returned to the Company.  The Company records the estimated fair value of the used laser   head as inventory and as an offset to cost of revenues upon receipt   thereof.  During the six month period   ended June 30, 2006, the Company received used laser heads related to   previous sales with an estimated fair value of approximately $124,000.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|   | Warranty expense – during the six-month period ended   June 30, 2006, the warranty period expired on several of the lasers   previously sold by the Company without further costs being incurred by the   Company. As a result, the remaining warranty expense in the amount of   $119,000 accrued for these lasers was reversed through selling-related   expenses upon the expiration of the warranties.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| NOTE 3 | PER SHARE INFORMATION                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|   | Basic   income per common share is computed using the weighted average number of   common shares and contingently issuable shares (to the extent that all   necessary contingencies have been satisfied).  Diluted income per common share is computed using the weighted   average number of common shares, contingently issuable shares (to the extent   that all necessary contingencies have been satisfied), and common share   equivalents outstanding during each period. Common share equivalents,   including options and warrants to purchase Common Stock, are included in the   computation using the treasury stock method. The dilutive effect of   convertible debt securities is computed using the if-converted method. The   computation of dilutive earnings per share excludes the effect of the assumed   conversion or exercise or contingent issuance of securities that would have   an antidilutuve effect on earnings per share. 473,000shares attributable to outstanding stock options and warrants   were excluded from the calculation of diluted earnings per share because the   exercise prices of the stock options and warrants were greater than or equal   to the average price of common shares during the period, and therefore   inclusion would have been antidilutive. |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| NOTE 4 | INVENTORIES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|   | Inventories, which consist primarily of excimer and   erbium laser systems and related parts and components, are stated at the   lower of cost or market.  Cost is   determined using the first-in first-out method.  The components of inventories at June 30, 2006 are summarized   as follows:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

|              |   | **June 30,   2006** |      |
|-------------------|--------|---------------------|-----------|
|              |   |                     |           |   |
| Raw   material    |   | $                   | 979,798   |   |
| Work   in Process |   |                | 604,506   |   |
| Finished   Goods  |   |                | 169,027   |   |
| Reserve           |   |                | (100,000  | ) |
|              |   |                     |           |   |
|              |   | $                   | 1,653,331 |   |
|              |   |                     |           |   |

Page 7

----

| NOTE  5 | AMENDED LOAN AGREEMENT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|--------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|         | The Company signed a three-year   note with Heller Healthcare Finance, Inc (“Heller”) and GE Healthcare   Financial Services, Inc., as successor-in-interest to Heller (collectively   “GE”) on August 30, 2004 (the “GE Note”). The GE Note was to expire on June   30, 2007.  The GE Note bore interest   of 9%.  The GE Note was secured by all   Company assets. The GE Note contained certain covenants, which required the   Company to maintain a minimum inventory balance of $1,500,000, minimum   quarterly revenues of $1,000,000 and an annual net income provision.  For the year ended December 31, 2005 and   any subsequent trailing twelve month periods, as measured on the last day of   each calendar quarter, the Company’s earnings before interest, taxes,   depreciation and amortization could not fall below $550,000. As of June 30,   2006, we were not in compliance with all covenants of our loan agreement with   GE. TheCompany had not met minimum quarterly revenue targets of $1,000,000,   a rolling twelve-month $550,000 of EBIDTA and had not presented a budget for   2006.                                                                                                                                                                                                                                         |
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|         | On June 7, 2006, the Company received a letter from   GE that advised the Company that, if not waived by GE within ten days, the   specified defaults would become “Events of Default” under the GE Note, which   would allow GE to accelerate the amounts due under the GE Note.  The   amount that would be due at that time was approximately $629,434, consisting   of $476,077 of principal and $153,357 of fees.  GE also presented the   Company a proposed Forbearance Agreement pursuant to which GE would forbear   from exercising its rights and remedies under the GE Note with respect to the   specified defaults until the earlier of (i) June 30, 2006, or (ii) the   occurrence or existence of Events of Default under the GE Note other than the   specified defaults.  Under that agreement, the Company would be required   to pay immediately a fee of $10,000, and an additional $10,000 would be added   to the indebtedness under the GE Note.  However,on June 13, 2006, GE   verbally agreed to waive the defaults without any additional charge to the   Company and to extend until July 31, 2006, the date on which the specified   defaults will become “Events of Default” under the GE Note. The Company   agreed to the terms of the waiver letter and pursued alternative financing   arrangements during this waiver period. |
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|         | The Company and its subsidiary, LaserSight   Technologies, Inc. (together, the “Borrowers”) entered into a Loan Agreement   (the “NIIC Loan Agreement”) with New Industries Investment Consultants (HK)   Ltd. (the “Lender”), an affiliate of the Company (see Note 6), dated as of   July 26, 2006.  The Lender advanced funds in the amount of $750,000.00   to the Company on that date.  The purpose of the loan transaction was to   allow the Company to pay in full its obligations to GE under the GE Note. The   NIIC Loan Agreement enabled the Company to meet the GE deadline and avoid   paying any additional fees. On July 27, 2006 the Company paid off the GE Note   balance and related fees in full, with a cash payment of $575,561.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|         | The NIIC Loan Agreement provides for a loan to the   Company (the “Loan”) in the maximum principal amount of $3,000,000, with an   initial disbursement to the Company of $750,000.  Interest of nine   percent (9%) per annum will accrue on the unpaid balance of the Loan, and   such interest and the entire balance of principal, fees, costs and expenses   shall be due and payable on June 30, 2007 (the “Maturity Date”).  The   Loan may be prepaid, in full or in part, without penalty.  The Company   agreed to pay a fee to the Lender of $15,000, as well as the Lender’s   reasonable transaction costs related to the Loan, all of which will be due on   the Maturity Date.  If not paid by the Maturity Date, the unpaid balance   of the Loan will bear interest at the rate of twelve percent (12%) per annum.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|         | Other terms and conditions of the Loan are nearly   identical to the terms and conditions set forth in the Promissory Note and   Security Agreement dated December 1, 2003, and the Restated Promissory Note   dated August 31, 2004, made by the Borrowers in favor of the Lender (the   “Prior Loan Documents”) (see Note 6).  Such terms and conditions from the Prior Loan   Documents were incorporated by reference into the NIIC Loan Agreement, to the   extent that such terms and conditions do not conflict with the terms and   conditions specifically set forth in the NIIC Loan Agreement.  However,   one significant difference is that the Loan is not convertible into shares of   the common stock of the Company.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

Page 8

----

|   | GE was issued a warrant to   purchase 100,000 shares of common stock at $0.25 per share, or $0.40 per   share if the New Industries Investment Group (see Note 6), converts its DIP   loan to equity.  The warrant expires   June 30, 2008.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| NOTE 6 | CHINA BACKGROUND                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|   | Shenzhen New Industries Medical Development Co.,   Ltd. (“NIMD”) was founded and incorporated by the Medical Investment   Department in 1995 by its parent company, New Industries Investment Group   (“NII”) of the People’s Republic of China. It specializes in marketing and   distribution of LASIK surgery devices and equipment, as well as in investment   and operation of LASIK clinical centers in Chinese market.                                                                                                                                                                                                                                                                                                                                                                                                                            |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|   | In the past decade, NIMD invested and operated   PRK/LASIK excimer laser refractive surgery centers in joint venture with   hospitals and medical institutes in China. New Industries Investment   Consultants (H.K.) Ltd (“NIIC”) specializes in hi-tech business investment   and consulting services. It is registered in Hong Kong. It was incorporated   in 1994 by its principal investor Mr. Xianding Weng (a major shareholder of   NII, NII’s CEO and the Company’s Chairman of the Board of Directors). NIIC,   NII and NIMD are collectively referred to herein as the “China Group”.                                                                                                                                                                                                                                                    |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|   | In 2003 and 2004, the China Group provided $2   million of debtor-in-possession (“DIP”) financing to the Company.  On June 30, 2004, $1 million of the DIP   financing was converted into 6,850,000 shares of common stock. In July 2006,   the China Group provided another $750,000 of financing, (see Note 5).  As of June 30, 2006, the China Group   controlled approximately 72% of the Company’s common stock.  Company revenues from the China Group were   approximately $0 and $183,000 in the three months and six months ended June   30, 2006, and were approximately $1.1 million and $3.0 million in the three   months and six months ended June 30, 2005, respectively.  Accounts receivable due from the China   Group as of June 30, 2006 was $10,657, virtually all of the accounts   receivable balance at June 30, 2006. |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| NOTE 7 | STOCK BASED COMPENSATION                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|   | The Company accounts for share based payments made   to employees in accordance with SFAS 123 (R) “Share-based Payments” which   requires all share-based payments to employees, including grants of employee   stock options, to be recognized in the income statement based on their fair   values. The fair value is typically recorded as unearned stock based   compensation and then amortized to expense over the vesting period.                                                                                                                                                                                                                                                                                                                                                                                                                                |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|   | The per share weighted-average fair value of stock   options granted during the year ended December 31, 2005, was approximately   $0.21, on the dates of grant using the Black Scholes option-pricing model   with the following weighted-average assumptions:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

|                    |   | **2005** |              |
|-------------------------|--------|----------|-------------------|
|                    |   |          |                   |   |
| Expected dividend yield |   |     | 0%                |   |
| Volatility              |   |     | 1,383 %  - 1,503% |   |
| Risk-free interest rate |   |     | 4.47   - 4.67%    |   |
| Expected life (years)   |   |     | 10                |   |

Page 9

----

|   | In May 2005 and December 2005, the Board of   Directors approved the issuance of options to purchase 498,000 shares and   69,813 shares, respectively, of the Company’s Common Stock with an estimated   fair value of approximately $119,000.    The options were issued to employees and Directors and have various   vesting schedules, but all are exercisable for ten years. Amortization of   unearned stock-based compensation for the three and six months ended June 30,   2006 was $9,219 and $20,249, respectively. Amortization of unearned   stock-based compensation for the three and six months ended June 30, 2005 was   $0. During 2006 the Company has not issued any employee stock options.                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| NOTE 8 | CONTINGENCIES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|   | Liquidity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|   | The Company incurred a net loss and had negative   cash flows during the six-months ended June 30, 2006 and had an accumulated   deficit of approximately $108 million at June 30, 2006.  Additionally, the Company’s revenues declined   and are significantly dependant upon NIMD (see Notes 6 and 10).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|   | Accordingly, the Company’s ability to continue as a   going concern is uncertain and dependent upon achieving improved operating   results and cash flows or obtaining additional equity capital and/or debt   financing.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|   | Litigation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|   | Italian Distributor.  In February 2003, an Italian court issued an order restraining   LaserSight Technologies from marketing our AstraPro software at a trade show   in Italy.  This restraining order was   issued in favor of LIGI Tecnologie Medicali S.p.a. (LIGI), a distributor of   our products, and alleged that our AstraPro software product infringes   certain European patents owned by LIGI.    We had retained Italian legal counsel to defend us in this litigation,   and we were informed that the Italian court had revoked the restraining order   and ruled that LIGI must pay our attorney’s fees in connection with our   defense of the restraining order.  In   addition, our Italian legal counsel informed us that LIGI had filed a motion   for a permanent injunction. We believe that our AstraPro software does not   infringe the European patents owned by LIGI, but due to limited cash flow the   Company has not defended its position. Management believes that the outcome of this litigation will not have   a material adverse impact on LaserSight’s business, financial condition or   results from operations. |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|   | Routine Matters*.*    In addition, we are involved from time to time in routine litigation   and other legal proceedings incidental to our business.  Although no assurance can be given as to   the outcome or expense associated with any of these proceedings, we believe   that none of such proceedings, either individually or in the aggregate, will   have a material adverse effect on the financial condition of LaserSight.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| NOTE 9 | SEGMENT INFORMATION                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|   | The Company’s operations principally include   refractive products.  Refractive   product operations primarily involve the development, manufacture and sale of   ophthalmic lasers and related devices for use in vision correction   procedures.  Patent services involve   the revenues and expenses generated from the ownership of certain refractive   laser patents.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|   | Operating profit is total revenue less operating   expenses.  In determining operating   profit for operating segments, the following items have not been   considered:  general corporate   expenses, non-operating income and expense and income tax expense.   Identifiable assets by operating segment are those that are used by or   applicable to each operating segment.    General corporate assets consist primarily of deferred financing   costs.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

Page 10

----

|  The table below summarizes information about   reported segments as of and for the three and six months ended June 30, 2006   and 2005: |
|-----------------------------------------------------------------------------------------------------------------------------------------------|

SEGMENT INFORMATION

Three months ended June 30,

|                  |   | **Operating   Revenues** |               | **Operating   Profit (Loss)** |   | **Assets** |   | **Depreciation   and Amortization** |               | **Capital   Expenditures** |   |
|-----------------------|--------|--------------------------|--------------------|-------------------------------|--------|------------|--------|-------------------------------------|--------------------|----------------------------|--------|
|                  |   |                          |                    |                          |        |            |   |                                     |                    |                       |        |  |   |  |  |   |
| 2006                  |   |                     |               |                          |   |       |   |                                |               |                       |   |   |   |   |   |   |
| Operating   segments: |   |                     |               |                          |   |       |   |                                |               |                       |   |   |   |   |   |   |
| Refractive products   |   | $                        | 99,321             |                          | $      | (191,150   | )      | $                                   | 2,692,049          |                       | $      | 12,578 |   |   | —   |   |
| Patent services       |   |                     | 197,207            |                          |   | 197,207    |   |                                | —   |                       |   | —   |   |   | —   |   |
| General corporate     |   |                     | —   |                          |   | (164,030   | )      |                                | 111,337            |                       |   | 28,158 |   |   | —   |   |
|                  |   |                          |                    |                          |        |            |   |                                     |                    |                       |        |  |   |  |  |   |
| Consolidated   total  |   | $                        | 296,528            |                          | $      | (157,973   | )      | $                                   | 2,803,386          |                       | $      | 40,736 |   | $ | —   |   |
|                  |   |                          |                    |                          |        |            |   |                                     |                    |                       |        |  |   |  |  |   |
| 2005                  |   |                     |               |                          |   |       |   |                                |               |                       |   |   |   |   |   |   |
| Operating   segments: |   |                     |               |                          |   |       |   |                                |               |                       |   |   |   |   |   |   |
| Refractive products   |   | $                        | 1,245,168          |                          | $      | 123,825    |   | $                                   | 4,871,618          |                       | $      | 17,024 |   |   | 923 |   |
| Patent services       |   |                     | 270,707            |                          |   | 270,707    |   |                                | —   |                       |   | —   |   |   | —   |   |
| General corporate     |   |                     | —   |                          |   | (220,443   | )      |                                | 222,674            |                       |   | 26,558 |   |   | —   |   |
|                  |   |                          |                    |                          |        |            |   |                                     |                    |                       |        |  |   |  |  |   |
| Consolidated   total  |   | $                        | 1,515,875          |                          | $      | 174,089    |   | $                                   | 5,094,292          |                       | $      | 43,582 |   |   | 923 |   |
|                  |   |                          |                    |                          |        |            |   |                                     |                    |                       |        |  |   |  |  |   |

Six months ended June 30

|                  |   | **Operating   Revenues** |               | **Operating   Profit (Loss)** |   | **Assets** |   | **Depreciation   and Amortization** |               | **Capital   Expenditures** |   |
|-----------------------|--------|--------------------------|--------------------|-------------------------------|--------|------------|--------|-------------------------------------|--------------------|----------------------------|--------|
|                  |   |                          |                    |                          |        |            |   |                                     |                    |                       |        |  |   |  |  |   |
| 2006                  |   |                     |               |                          |   |       |   |                                |               |                       |   |   |   |   |   |   |
| Operating   segments: |   |                     |               |                          |   |       |   |                                |               |                       |   |   |   |   |   |   |
| Refractive products   |   | $                        | 521,323            |                          | $      | (551,098   | )      | $                                   | 2,692,049          |                       | $      | 25,155 |   |   | —   |   |
| Patent services       |   |                     | 391,298            |                          |   | 391,298    |   |                                | —   |                       |   | —   |   |   | —   |   |
| General corporate     |   |                     | —   |                          |   | (245,945   | )      |                                | 111,337            |                       |   | 56,317 |   |   | —   |   |
|                  |   |                          |                    |                          |        |            |   |                                     |                    |                       |        |  |   |  |  |   |
| Consolidated   total  |   | $                        | 912,621            |                          | $      | (405,745   | )      | $                                   | 2,803,386          |                       | $      | 81,472 |   | $ | —   |   |
|                  |   |                          |                    |                          |        |            |   |                                     |                    |                       |        |  |   |  |  |   |
| 2005                  |   |                     |               |                          |   |       |   |                                |               |                       |   |   |   |   |   |   |
| Operating   segments: |   |                     |               |                          |   |       |   |                                |               |                       |   |   |   |   |   |   |
| Refractive products   |   | $                        | 3,152,558          |                          | $      | 311,753    |   | $                                   | 4,871,618          |                       | $      | 31,025 |   | $ | 2,573 |   |
| Patent services       |   |                     | 531,212            |                          |   | 531,212    |   |                                | —   |                       |   | —   |   |   | —   |   |
| General corporate     |   |                     | —   |                          |   | (489,902   | )      |                                | 222,674            |                       |   | 52,316 |   |   | —   |   |
|                  |   |                          |                    |                          |        |            |   |                                     |                    |                       |        |  |   |  |  |   |
| Consolidated   total  |   | $                        | 3,683,770          |                          | $      | 353,063    |   | $                                   | 5,094,292          |                       | $      | 83,341 |   | $ | 2,573 |   |
|                  |   |                          |                    |                          |        |            |   |                                     |                    |                       |        |  |   |  |  |   |

Page 11

----

| NOTE 10 | REGISTRATION OF PRODUCT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|    | The Company started the renewal registration process   to sell our laser products in China in early 2005. Our laser product registration   in China expired in December 2005.    Until we receive the renewal of the product registration, we cannot   sell our laser products in China.                                                                                                                                                                                                                         |
|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|    | After responding to requests for more information   from the State Food and Drug Administration in China and conducting tests at   a government-selected laboratory, our application for renewal was accepted in   early 2006.  We expect the renewal   will be granted in the third quarter of 2006.                                                                                                                                                                                                            |
|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|    | Our product CE certificate expired in February of   2006, and we are also in the process of renewing this certificate. We cannot   sell our products to customers where CE certification is required until we   receive the renewed certificate. We expect to receive our CE certificate in   the third quarter of 2006.                                                                                                                                                                                              |
|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|    | We received the Registration Certificate to market   our AstraMax (the corneal topography system) in China on March 8, 2006.                                                                                                                                                                                                                                                                                                                                                                                          |
|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|    | We also received the renewed EC Certificates for our   LaserScan LSX (the laser) and AstraMax (the corneal topography system) on   July 25, 2006.                                                                                                                                                                                                                                                                                                                                                                     |
|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| NOTE 11 | NEW BUSINESS MODEL DEVELOPMENT IN CHINA                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|    | The Company is currently developing and evaluating a   revenue-sharing business model (Per Procedure Fees charged to users, the   “PPF” model) with the Company’s users in China. To capitalize on the fast   growth of the procedure volumes in China’s market, management believes that   this business model will provide the Company with a long-term steady cash   flow and better profitability from the market. This revised business model   would be implemented on a prospective basis. |
|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|    | Using the similar concept, we have recently launched   our custom-ablation software package AstraPro (cornea topography guided   custom-ablation) in China with the charge of per procedure fees to the users   (Custom-ablation Per Procedure Fees, or the “CPPF” model) to capitalize on   the increasing use of the custom-ablation procedures with long-term revenue from the   users.                                                                                                                  |

Page 12

----

**Item 2.       Management’s Discussion and Analysis or Plan** **of Operation**.

**Forward-Looking Statements and Associated Risks**

*THIS QUARTERLY REPORT ON FORM 10-QSB CONTAINS FORWARD-LOOKING STATEMENTS THAT HAVE BEEN MADE PURSUANT TO THE PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995.  THESE FORWARD-LOOKING STATEMENTS ARE BASED ON MANAGEMENT’S CURRENT EXPECTATIONS, ESTIMATES AND PROJECTIONS, BELIEFS AND ASSUMPTIONS. WORDS SUCH AS “ANTICIPATES”, “EXPECTS”, “INTENDS”, “PLANS”, “BELIEVES”, “SEEKS”, “ESTIMATES”, VARIATIONS OF SUCH WORDS AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY SUCH FORWARD-LOOKING STATEMENTS.  THESE STATEMENTS ARE NOT GUARANTEES OF FUTURE PERFORMANCE AND ARE SUBJECT TO CERTAIN RISKS, UNCERTAINTIES AND ASSUMPTIONS THAT ARE DIFFICULT TO PREDICT; THEREFORE, ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE EXPRESSED OR FORECASTED IN ANY SUCH FORWARD-LOOKING STATEMENTS.  THESE RISKS AND UNCERTAINTIES INCLUDE THOSE DISCUSSED IN “PART I – ITEM 1 –DESCRIPTION OF BUSINESS – RISK FACTORS” AND, “PART II – ITEM 6 – MANAGEMENT’S DISCUSSION AND ANALYSIS OR PLAN  OF OPERATION” CONTAINED IN THE COMPANY’S FORM 10-KSB FOR THE YEAR ENDED DECEMBER 31, 2005, AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.  UNLESS REQUIRED BY LAW, THE COMPANY UNDERTAKES NO OBLIGATION TO UPDATE PUBLICLY ANY FORWARD-LOOKING STATEMENTS, WHETHER AS A RESULT OF NEW INFORMATION, FUTURE EVENTS OR OTHERWISE.  INVESTORS SHOULD REVIEW THIS QUARTERLY REPORT IN COMBINATION WITH THE COMPANY’S ANNUAL REPORT ON FORM 10-KSB IN ORDER TO HAVE A MORE COMPLETE UNDERSTANDING OF THE PRINCIPAL RISKS ASSOCIATED WITH AN INVESTMENT IN THE COMPANY’S STOCK.*

**Overview**

          LaserSight is principally engaged in the manufacture and supply of narrow beam scanning excimer laser systems, topography-based diagnostic workstations, and other related products used to perform procedures that correct common refractive vision disorders such as nearsightedness, farsightedness and astigmatism.  Since 1994, we have marketed our laser systems commercially in over 30 countries worldwide.  We are currently focused on selling in selected international markets; primarily China.

          We have significant liquidity and capital resource issues relative to the timing of our accounts receivable collection and the successful completion of new sales compared to our ongoing payment obligations and our recurring losses from operations and net capital deficiency raises substantial doubt about our ability to continue as a going concern.  We have experienced significant losses and operating cash flow deficits, and we expect that operating cash flow deficits will continue without improvement in our operating results.  

**Bankruptcy**

          On September 5, 2003 we filed for Chapter 11 bankruptcy protection and reorganization.  We operated in this manner from September 5, 2003 through June 10, 2004, when the re-organization was approved by the Bankruptcy Court. A final decree of bankruptcy was obtained on December 22, 2004.  As a result of the bankruptcy re-structuring, we have recorded credits for debt forgiveness of approximately $15.3 million during the three months ended June 30, 2004.  Additionally, we recognized charges of approximately $8.0 million during 2003 for patent impairment, accounts receivable and inventory write offs.  We cancelled all of its outstanding common and preferred stock, including warrants and options, and issued 9,997,195 new common shares on June 30, 2004.  We emerged from bankruptcy with approximately $0.7 million in unsecured liabilities, approximately $2.1 million in secured debt,approximately $5.3 million in deferred revenue and approximately $1.0 million of DIP financing provided by a related party, as part of the approved bankruptcy plan.  The related party converted $1.0 million of the DIP financing for an additional 6,850,000 common shares. 

Page 13

----

**China Transaction**

          In February 2004, we received a commitment from a Shenzhen New Industries Medical Development Co., Ltd. (“NIMD”), related party purchaser, to purchase at least $12.0 million worth of our products during the 12-month period ending February 2005 and to distribute our products in Mainland China, Hong Kong, Macao and Taiwan.  The purchase agreement provides for two one-year extensions. From February 2004 through September 2005, approximately $10.1 million worth of products were sold under this agreement. Product issues reduced shipments during the third and fourth quarters of 2004 and the first and second quarters of 2005.  These issues have been resolved through revisions to product crating for shipment, software modifications and revised shipper instructions. An extension has not been signed, but the parties have continued to conduct business under similar terms as set forth in thepurchase agreement.

**WaveLight Transaction**

          In March 2005 we executed a worldwide non-exclusive license agreement with WaveLight Laser Technologie AG (“WaveLight”) to use and reproduce the Lin Scanning Patents for products to be used in ophthalmic surgery, which became effective on March 3, 2005, and an option to acquire a license to the Company’s Apple Patents. Both the non-exclusive license and the option include certain WaveLight co-enforcement rights. As consideration for the license, we had received payments totaling $900,000 by October 2005, and we will receive no additional payments. $45,000 in broker fees were paid to an unrelated party for their assistance in closing this transaction.  The agreement terminates when the patents expire, or earlier in the event of the occurrence of certain events of default. 

**New Business Model**

          Since the beginning of 2006, we have been developing a revenue-sharing business model with the users of our products in China, (Per Procedure Fees charged to users, or the “PPF” model). We believe this business model will provide us long-term, steady cash flow and better profitability and that it will allow us to capitalize on the fast growth of the procedure volumes in China’s market. This revised business model will be implemented on a prospective basis. The plan concept is to charge less at the original purchase date, but to charge a PPF fee over the life of the contract. To prepare for these changes in offering our business model, we  are considering seeking capital infusion by long-term loan or equity offering, and we are preparing detailed plans for our operations in China. We believe we will have some trial results of our PPF model in China in the third quarter of this year. Oursecond-quarter trial of the PPF model in China has achieved some positive results, especially in the market response to this business model.

          We have also recently launched our custom-ablation software package product, AstraPro (cornea topography guided custom-ablation), in China with a charge to users of a per procedure fee (Custom-ablation Per Procedure Fees, or the “CPPF” model) in order to capitalize on the increasing market for the custom-ablation procedures with long-term revenue from the users.

**Results of Operations**

          The following table sets forth for the periods indicated information derived from our statements of operations for those periods expressed as a percentage of net sales, and the percentage change in such items from the comparable prior year period.  Any trends illustrated in the following table are not necessarily indicative of future results.

Page 14

----

As a Percentage of Net Sales

|                                                |   | **Three   Months Ended   June 30,** |   | **Six Months   Ended   June 30,** |   | **Three   Months   Ended    June 30,** |   | **Six Months   Ended   June 30,** |   |
|-----------------------------------------------------|--------|-------------------------------------|--------|-----------------------------------|--------|----------------------------------------|--------|-----------------------------------|--------|
|                                                |   |                                     |   |                                   |   |                                        |        |                              |        |  |   |
|                                                |   | **2006**                            |   | **2005**                          |   | **2006**                               |   | **2005**                          |   | **2006 vs.   2005** |   |
|                                                |   |                                     |        |                              |        |                                        |   |                                   |        |   |  |  |   |  |   |
| **Statement of Operations Data:**                   |   |                                |   |                              |   |                                   |   |                              |   |   |   |   |   |   |   |   |   |   |   |
| Net   Revenues:                                     |   |                                |   |                              |   |                                   |   |                              |   |   |   |   |   |   |   |   |   |   |   |
| Refractive products                                 |   |                                | 33.5   | %                                 |   | 82.1                                   | %      |                              | 57.1   | % |   | 85.6 | % |   | -92.0 | % |   | -83.5 | % |
| Patent services                                     |   |                                | 66.5   | %                                 |   | 17.9                                   | %      |                              | 42.9   | % |   | 14.4 | % |   | -27.2 | % |   | -26.3 | % |
|                                                |   |                                     |        |                              |        |                                        |   |                                   |        |   |  |  |   |  |  |   |  |  |   |
| Net Revenues                                        |   |                                | 100.0  | %                                 |   | 100.0                                  | %      |                              | 100.0  | % |   | 100.0 | % |   | -100.0 | % |   | -75.2 | % |
| Cost   of Revenue                                   |   |                                | -4.7   | %                                 |   | 44.9                                   | %      |                              | 24.4   | % |   | 45.5 | % |   | -102.0 | % |   | -86.7 | % |
|                                                |   |                                     |        |                              |        |                                        |   |                                   |        |   |  |  |   |  |  |   |  |  |   |
| Gross   Profit (1)                                  |   |                                | 104.7  | %                                 |   | 55.1                                   | %      |                              | 75.6   | % |   | 54.5 | % |   | -62.8 | % |   | -65.6 | % |
| Research, development and regulatory   expenses (2) |   |                                | 17.5   | %                                 |   | 3.1                                    | %      |                              | 9.2    | % |   | 2.7 | % |   | 0.0 | % |   | -15.8 | % |
| Other   general and administrative  expenses   |   |                                | 180.1  | %                                 |   | 39.0                                   | %      |                              | 119.2  | % |   | 34.3 | % |   | -9.7 | % |   | -13.9 | % |
| Selling-related   expenses (3)                      |   |                                | -42.5  | %                                 |   | 0.9                                    | %      |                              | -10.2  | % |   | 7.4 | % |   | -992.5 | % |   | -134.1 | % |
| Amortization   of intangibles                       |   |                                | 2.8    | %                                 |   | 0.6                                    | %      |                              | 1.8    | % |   | 0.5 | % |   | 0.0 | % |   | 0.0 | % |
|                                                |   |                                     |        |                              |        |                                        |   |                                   |        |   |  |  |   |  |  |   |  |  |   |
| Net   Income from operations                        |   |                                | -53.3  | %                                 |   | 11.5                                   | %      |                              | -44.5  | % |   | 9.6 | % |   | -190.7 | % |   | -214.9 | % |

|        |
|--------|
| (1)    | As a percentage of   refractive products net revenues, the gross profit for refractive products   only for the three months ended June 30, 2006 and 2005 were approximately   114% and 45%, respectively. As a percentage of net revenues, the gross profit   for refractive products only for the six months ended June 30, 2006 and 2005   were approximately 57% and 47%, respectively. |
|   |   |
| (2)    | As a percentage of   refractive product net sales, research, development and regulatory expenses   for the three months ended June 30, 2006 and 2005, were approximately 52% and   4%, respectively.  As a percentage of   refractive product net sales, research, development and regulatory expenses   for the six months ended June 30, 2006 and 2005, were approximately 16% and   3%, respectively. |
|   |   |
| (3)    | As a percentage of   refractive product net sales, selling-related expenses for the three months   ended June 30, 2006 and 2005 were approximately (127%) and 1%, respectively.   As a percentage of refractive product net sales, selling-related expenses for   the six months ended June 30, 2006 and 2005 were approximately (18%) and 9%,   respectively. |

***Three Months Ended June 30, 2006, Compared to Three Months Ended June 30, 2005***

          Our consolidated revenues totaled approximately $0.3 million for the three months ended June 30, 2006, a decrease of approximately $1.2 million or 80% compared to revenues for the three months ended June 30, 2005 of approximately $1.5 million. The decrease was primarily attributable to decreased sales of laser systems as a result of the expiration of our product registration in China. No lasers systems or AstraMax systems were sold in the second quarter of 2006, and five were sold in the second quarter of 2005. For the three months ended June 30, 2006, parts revenues were $98,000 compared to $137,000 for the three months ended June 30, 2005. Our 2006 budget projected laser sales at 27 for the year.  Due to the product registration restriction and the new business model testing in China, we  adjusted  ourprojection  of  sales  to ship  13  lasers  and 18  AstraMax  ®  diagnosticworkstations  this  year,  but the sales will  occur  primarily  in the last sixmonths  of the year.  If we do not  receive  product  registration  renewals  asplanned, we may not be able to make and sell 13 lasers this year.

Page 15

----

          Net revenues from patent services decreased by approximately $73,000, or 27%, from approximately $271,000 for the three months ended June 30, 2005 to approximately $197,000 for the three months ended June 30, 2006. The reduction in royality revenues is due to a portion of the deferred revenue becoming fully amortized. During the first quarter of 2005, the Company licensed its Lin scanning patent for $855,000, net of expenses of $45,000. This deferred revenue is being amortized over the remaining life of the patent, approximately seven years. 

          Geographically, China has become our most significant market, even though there was no revenue from China during the three months ended June 30, 2006, as compared to approximately $1.1 million for the three months ended June 30, 2005.

          Consolidated cost of sales includes direct material costs, manufacturing wages, inbound freight, rework, scrap and standard cost variances.  For the three months ended June 30, 2006, consolidated cost of sales was ($13,000) on net revenues of $297,000, compared to the same period in 2005 when our cost of sales was approximately $681,000 or 45% of net revenues. For the three months ended June 30, 2006, consolidated cost of sales was ($13,000) on product revenues of $99,000, compared to the same period in 2005 when our cost of sales was approximately $681,000 or 55% of product revenues. The improvement of 2006 margins is primarily related to reclaimed inventory from returned lasers of $103,000 and returned deposits on gas cylinders of $11,000. For the remainder of 2006, our emphasis will be on continued unit cost reductions driven by efficient purchasing and limited re-design of our product. Ourgoal is to maintain a 47% consolidated cost of sales.

*          *Selling-related expenses consist of those items directly related to sales activities, including commissions on sales, royalty or license fees, warranty expenses, and costs of shipping and installation. Selling-related expenses for the three months ended June 30, 2006 decreased $140,000, or 993%, to ($126,000) from $14,000 during the three months ended June 30, 2005. This decrease was primarily attributable to reduced licensing fees, the reversal of warranty reserves, and lower shipping costs due to lower sales.  Our 2006 operating plan projected our selling-related expense ratio to be 11% of net revenues. For the three months ended June 30, 2006, selling-related expenses were lower primarily due to the reduction in the warranty reserve and shipping costs. Warranty reserves in the amount of $103,000 for lasers moving out of warranty during the three months ended June 30, 2006 were reversed inthe current period. Our current plan projects our selling-related expense ratio to be 9% of net revenues for the remainder of 2006. 

          General and administrative expenses decreased by $58,000, or 10%, to $534,000 in the three months ended June 30, 2006, from $591,000 for the same period in 2005. The decrease was primarily due to lower legal fees, and accounting fees, salaries and insurance premiums. The current plan projects our general and administrative expenses ratio to be 28% of net revenues. This is a higher percentage than our original budget, which is caused by general and administrative expenses remaining similar to our original projections with revenues becoming lower than originally forecasted.

          Research, development and regulatory expenses increased by $5,000 to $52,000 for the three months ended June 30, 2006 from $47,000 for the three months ended June 30, 2005. The increase was for unplanned material purchases to assist with the CE mark testing. Our operating plan for fiscal 2006 projected business levels that would require research, development and regulatory expenses to be similar to 2005. 

          In the three months ended June 30, 2006, amortization of intangibles remained unchanged at $8,400. In accordance with our operating plan, amortization of intangibles will be at a rate of approximately $33,000 per year. 

Page 16

----

Other income and expense for the three months ended June 30, 2006 consisted of the following: 

|   | • | We received $396 of interest income on notes   receivable.                                                                                                                                                                                                                                                                                                                |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                                                                                                                                                                                                                                      |
|   | • | In the three   months ended June 30, 2006, we accrued $65,000 in interest expense.  All of the accrued interest was paid except   for $22,500 of accrued interest for the DIP financing. The interest expense   includes $28,000 of amortized financing costs.  The amortization of financing costs is $8,600 per month and   will continue until June of 2007. |

          For the three months ended June 30, 2006 and 2005, we had no income tax expense due to our net operating loss carryforwards.

          Net loss for the three months ended June 30, 2006 was approximately $223,000 compared to a $93,000 net income for the same period in 2005, a decrease of approximately $316,000. This $316,000 decrease in the current quarter was comprised approximately of: 

|   | • | decreased gross profit of $525,000 due to lower   revenues.                                                                                                                                |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                                                       |
|   | • | decreased G&A expenses of $58,000 due to lower   insurance, salaries & professional fees, offset by higher board of   director fees and audit fees added   to the GE note payable. |
|   |   |                                                                                                                                                                                       |
|   | • | decreased interest expense of $17,000 due to lower   loan balances.                                                                                                                        |
|   |   |                                                                                                                                                                                       |
|   | • | increased R&D expenses of $5,000 to purchase   materials for CE mark process.                                                                                                          |
|   |   |                                                                                                                                                                                       |
|   | • | decreased selling-related expenses of $140,000   related to reduced warranty estimates and unit shipping charges.                                                                          |

***Six Months Ended June 30, 2006, Compared to Six Months Ended June 30, 2005***

          Our     consolidatedrevenues  totaled  approximately  $0.9 million for the six months ended June 30,2006, a decrease of  approximately  $2.8 million or 75% compared to revenues forthe six months ended June 30, 2005 of approximately  $3.7 million.  The decreasewas  primarily  attributable  to decreased  sales of laser  systems.  Two laserssystems were sold in the first half of 2006,  and 13 were sold in the first halfof 2005.  For the six months ended June 30, 2006,  parts  revenues were $129,000compared to $161,000 for the six months ended June 30, 2005.  This also includeda $0.1  million  reduction  in sales of our  AstraMax ®  diagnosticworkstation;  no AstraMax  sales were  recorded in the six months ended June 30,2006  compared  to four  for the  comparable  period  in 2005.  Our 2006  budgetprojected laser sales at 27 for the year.   Due to the product registrationrestriction  and the new  business  model  testing  in China,  we  adjusted  ourprojection  of  sales  to ship  13  lasers  and 18  AstraMax  ®  diagnosticworkstations  this  year,  but the sales will  occur  primarily  in the last sixmonths  of the year.  If we do not  receive  product  registration  renewals  asplanned, we may not be able to make and sell 13 lasers this year.

          Net revenues from patent services decreased by approximately $140,000, or 26%, from approximately $531,000 for the six months ended June 30, 2005 to approximately $391,000 for the six months ended June 30, 2006. The reduction in royalty revenue is due to a portion of the deferred revenue becoming fully amortized. During the first quarter of 2005, the Company licensed its Lin scanning patent for $855,000, net of expenses of $45,000. This deferred revenue is being amortized over the remaining life of the patent, approximately seven years. 

Page 17

----

          Geographically, China has become our most significant market, with $183,000 in revenue during the six months ended June 30, 2006, as compared to approximately $3.0 million for the six months ended June 30, 2005.

          Consolidated cost of sales includes direct material costs, manufacturing wages, inbound freight, rework, scrap and standard cost variances.  For the six months ended June 30, 2006, consolidated cost of sales of $223,000 was approximately 24% of net revenues of $913,000, compared to the same period in 2005 when our cost of sales was approximately 45% of net revenues. For the six months ended June 30, 2006, consolidated cost of sales of $223,000 was approximately 43% of product revenues of $521,000, compared to the same period in 2005 when our cost of sales was approximately 53% of product revenues. The improvement of 2006 margins is primarily related to improved margins on part sales, return of deposits on gas cylinders of $11,000 and reclaimed inventory from returned lasers of $124,000. For the remainder of 2006, our emphasis will be on continued unit cost reductions driven by efficient purchasingand limited re-design of our product. Our goal is to maintain a 47% consolidated cost of sales.

*          *Selling-related expenses consist of those items directly related to sales activities, including commissions on sales, royalty or license fees, warranty expenses, and costs of shipping and installation. Selling-related expenses for the six months ended June 30, 2006 decreased $367,000, or 134%, to ($93,000) from $273,000 during 2005. This decrease was primarily attributable to reduced licensing fees, the reversal of warranty reserves and lower shipping costs due to lower sales.  During the six-month period ended June 30, 2006, the warranty period expired on several of the lasers previously sold by the Company without further costs being incurred by the Company. As a result, the remaining warranty expense accrued for these lasers in the amount of $124,000 was reversed through selling-related expenses upon the expiration of the warranties. Our 2006 operating plan projected our selling-relatedexpense ratio to be 11% of net revenues. For the six months ended June 30, 2006, selling-related expenses were lower primarily due to the reduction in the warranty reserve and shipping costs. Warranty reserves in the amount of $121,000 for lasers moving out of warranty during the six months ended June 30, 2006, were reversed in the current period. Our current plan projects our selling-related expense ratio to be 9% of net revenues for the remainder of 2006. 

          General and administrative expenses decreased by $176,000, or 14%, to $1.1 million in the six months ended June 30, 2006, from $1.3 million for the same period in 2005. The decrease was primarily due to lower legal fees, and accounting fees, salaries and insurance premiums. The current plan projects our general and administrative expenses ratio to be 28% of net revenues. This is a higher percentage than our original budget, which is caused by general and administrative expenses remaining similar to our original projections with revenues becoming lower than originally forecasted.

          Research, development and regulatory expenses decreased by $16,000 to $84,000 for the six months ended June 30, 2006 from $100,000 for the six months ended June 30, 2005. Even though our resources are limited, we continue to offer improvements to our product, and we were required to make unplanned material purchases for the CE mark testing effort. Our operating plan for fiscal 2006 projected business levels that would require research, development and regulatory expenses to be similar to 2005. However, limited cash in-flows and efforts needed by the engineering team to assist with the CE mark registration process have delayed development activities. 

          In the six months ended June 30, 2006, amortization of intangibles remained unchanged at $16,800. In accordance with our operating plan, amortization of intangibles will be at a rate of approximately $33,000 per year. 

          Other income and expense for the six months ended June 30, 2006 consisted of the following: 

|   | • | We received $6,503 of interest income on notes   receivable.                                                                                                                                                                                                                                                                                                             |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                                                                                                                                                                                                                                     |
|   | • | $6,108 was   received as abandoned property from various states.                                                                                                                                                                                                                                                                                                         |
|   |   |                                                                                                                                                                                                                                                                                                                                                                     |
|   | • | In the six months   ended June 30, 2006, we accrued $135,000 in interest expense.  All of the accrued interest was paid   except for $45,000 of accrued interest for the DIP financing. The interest   expense includes $56,000 of amortized financing costs.  The amortization of financing costs is   $8,600 per month and will continue until June of 2007. |

Page 18

----

          For the six months ended June 30, 2006 and 2005, we had no income tax expense due to our net operating loss carry-forwards.

          Net loss for the six months ended June 30, 2006 was approximately $534,000 compared to a $184,000 net income for the same period in 2005, a decrease of approximately $718,000. This $718,000 decrease in the first half of 2006 was comprised approximately of: 

|   | • | decreased gross profit of $1.3 million due to lower   revenues.                                                                                                                                                                                                             |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                                                                                                                                        |
|   | • | decreased G&A expenses of $202,000 due to lower   insurance, lease expense and professional fees for auditing and tax   preparation, as well as 2005 annual shareholder meeting expenses, which did   not occur in 2006, and audit fees added   to the GE note payable. |
|   |   |                                                                                                                                                                                                                                                                        |
|   | • | decreased interest expense of $36,000 due to lower   loan balances.                                                                                                                                                                                                         |
|   |   |                                                                                                                                                                                                                                                                        |
|   | • | decreased selling related expenses of $367,000   related to reduced warranty estimates and unit shipping charges.                                                                                                                                                           |

**Inflation and Currency Fluctuation**

          Inflation and currency fluctuations have not previously had a material impact upon the results of operations and are not expected to have a material impact in the near future.

**Liquidity and Capital Resources**

          On September 5, 2003 we filed for Chapter 11 bankruptcy protection and reorganization. We operated in this manner from September 5, 2003 through June 10, 2004, when the re-organization was approved by the Bankruptcy Court, effective June 30, 2004. A final decree of bankruptcy was obtained on December 22, 2004. We cancelled all of our outstanding common and preferred stock, including warrants and options, and issued 9,997,195 new common shares on June 30, 2004.  We emerged from bankruptcy with approximately $0.7 million in unsecured liabilities, approximately $2.1 million in secured debt, approximately $5.3 million in deferred revenue and approximately $1.0 million of DIP financing provided by NIIC.  NIIC converted $1.0 million of the DIP financing for additional equity.  

          With the new revenues expected from the China Group and projected sales to other customers, management expects that our cash and cash equivalent balances and funds from operations (which are principally the result of sales and collection of accounts receivable) may not be sufficient to meet our anticipated operating cash requirements for the next several months. Our plans include the raising of additional capital through the issuance of debt or equity to finance the new business model. This expectation is based upon assumptions regarding cash flows and results of operations over the next several months and is subject to substantial uncertainty and risks beyond our control. If these assumptions prove incorrect, the duration of the time period during which we could continue operations could be materially shorter.

           The Company started the renewal registration process to sell our laser products in China in early 2005. Our laser product registration in China expired in December 2005.  Until we receive the renewal of the product registration, we cannot sell our laser products in China. After responding to requests for more information from the State Food and Drug Administration in China and conducting tests at a government selected laboratory, our application for renewal was accepted in early 2006.  We expect the renewal will be granted in the third quarter of 2006. Our product CE certificate expired in February 2006, and renewed in July 2006. 

Page 19

----

          We continue to face liquidity and capital resource issues relative to the timing of the successful completion of new sales compared to our ongoing payment obligations.  To continue our operations, we will need to generate increased revenues, collect them and reduce our expenditures relative to our recent history.  While we are working to achieve these improved results, we cannot give assurances that we will be able to generate increased revenues and collections to offset required cash expenditures.  Our revenues from the China Group were approximately $178,000 in the six-months ended June 30, 2006. Accounts receivable due from the China Group as of June 30, 2006 totaled $10,000, which was virtually all of our accounts receivable balance at June 30, 2006. $10,657 of the China Group’s balance is over ninety days past due. As of August 11, 2006, $10,657 of the accounts receivablebalance remains unpaid.  While we have verbal promises from the China Group to pay the accounts receivable balance, and management continues to believe that we will fully realize the balance due, the ultimate realization thereof can not be assured. The loss of the China Group as a customer or the non-payment or slow payment of monies owed to us could have a significant adverse effect on our ability to continue as a going concern.

          The Company signed a three-year note with Heller Healthcare Finance, Inc (“Heller”) and GE Healthcare Financial Services, Inc., as successor-in-interest to Heller (collectively “GE”) on August 30, 2004 (the “GE Note”). The GE Note was to expire on June 30, 2007.  The GE Note bore interest of 9%.  Covenants required the Company to maintain a minimum inventory balance of $1,500,000, minimum quarterly revenues of $1,000,000 and an annual net income provision.  For the year ended December 31, 2005 and any subsequent trailing twelve month periods, as measured on the last day of each calendar quarter, the Company’s earnings before interest, taxes, depreciation and amortization could not fall below $550,000. As of June 30, 2006, we were not in compliance with all covenants of our loan agreement. The Company had not met minimum quarterly revenue targets of$1,000,000, a rolling twelve-month $550,000 of EBIDTA and had not presented a budget for 2006.

          On June 7, 2006, the Company received a letter GE advised the Company that, if not waived by GE within ten days, the specified defaults would become “Events of Default” under the GE Note, which would allow GE to accelerate the amounts due under the GE Note.  The amount that would be due at that time was approximately $629,434, consisting of $476,077 of principal and $153,357 of fees.  GE also presented the Company a proposed Forbearance Agreement pursuant to which GE would forbear from exercising its rights and remedies under the GE Note with respect to the specified defaults until the earlier of (i) June 30, 2006, or (ii) the occurrence or existence of Events of Default under the GE Note other than the specified defaults.  Under that agreement, the Company would be required to pay immediately a fee of $10,657, and an additional $10,000 would be added to the indebtedness underthe GE Note.  However, on June 13, 2006, GE verbally agreed to waive the defaults without any additional charge to the Company and to extend until July 31, 2006, the date on which the specified defaults will become “Events of Default” under the GE Note.  The Company agreed to the terms of the waiver letter and pursued alternative financing arrangements during this waiver period.

          The Company and its subsidiary, LaserSight Technologies, Inc., (together, the “Borrowers”) entered into a Loan Agreement (the “NIIC Loan Agreement”) with New Industries Investment Consultants (HK) Ltd. (the “Lender”), an affiliate of the Company, dated as of July 26, 2006.  The Lender advanced funds in the amount of $750,000.00 to the Company on that date.  The purpose of the loan transaction was to allow the Company to pay in full its obligations to GE under the GE Note. The NIIC Loan Agreement enabled the Company to meet the GE deadline and avoid paying any additional fees. On July 27, 2006 the Company paid off the GE Note balance in full, with a cash payment of $575,561.

          The NIIC Loan Agreement provides for a loan to the Company (the “Loan”) in the maximum principal amount of $3,000,000, with an initial disbursement to the Company of $750,000.  Interest of nine percent (9%) per annum will accrue on the unpaid balance of the Loan, and such interest and the entire balance of principal, fees, costs and expenses shall be due and payable on June 30, 2007 (the “Maturity Date”).  The Loan may be prepaid, in full or in part, without penalty.  The Company agreed to pay a fee to the Lender of $15,000, as well as the Lender’s reasonable transaction costs related to the Loan, all of which will be due on the Maturity Date.  If not paid by the Maturity Date, the unpaid balance of the Loan will bear interest at the rate of twelve percent (12%) per annum.

Page 20

----

          Other terms and conditions of the Loan are nearly identical to the terms and conditions set forth in the Promissory Note and Security Agreement dated December 1, 2003, and the Restated Promissory Note dated August 31, 2004, made by the Borrowers in favor of the Lender (the “Prior Loan Documents”).  Such terms and conditions from the Prior Loan Documents were incorporated by reference into the NIIC Loan Agreement, to the extent that such terms and conditions do not conflict with the terms and conditions specifically set forth in the NIIC Loan Agreement.  However, one significant difference is that the Loan is not convertible into shares of the common stock of the Company.

          There can be no assurance as to the correctness of the assumptions underlying our business plan or our expectations regarding our working capital requirements or our ability to continue operations.  Our ability to continue operations is based on factors including the success of our sales efforts in China and in other foreign countries where our efforts will initially be primarily focused, increases in accounts receivable and inventory purchases when sales increase, the uncertain impact of the market introduction of our AstraMax diagnostic workstations, and the absence of unanticipated product development and marketing costs.

          During the six months ended June 30, 2006 operating cash flow was positive primarily due to collections of accounts receivable. However, our change in cash was negative primarily due to payments on notes payable.  Our expectations regarding future working capital requirements and our ability to continue operations are based on various factors and assumptions that are subject to substantial uncertainty and risks beyond our control, and no assurances can be given that these expectations will prove correct.  The occurrence of adverse developments related to these risks and uncertainties or others could result in our incurring unforeseen expenses, being unable to generate additional sales, to collect new and outstanding accounts receivable, to control expected expenses and overhead, or to negotiate payment terms with creditors, and we would likely be unable to continue operations.  

| **Item 3.** | **Controls and Procedures.** |
|-------------|------------------------------|

          We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. 

          We carry out a variety of on-going procedures, under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, to evaluate the effectiveness of the design and operation of our disclosure controls and procedures. Our Chief Executive Officer and Chief Financial Officer have concluded that such controls and procedures are currently effective at the reasonable assurance level.

Page 21

----

**PART II - OTHER INFORMATION**

| **Item 1** | **Legal Proceedings.** |
|------------|------------------------|

          Certain legal proceedings against LaserSight are described in Item 3 (Legal Proceedings) of LaserSight’s Form 10-KSB for the year ended December 31, 2005, and in Note 9 to the Financial Statements in Part I, Item 1 of this report, which are incorporated herein by this reference.

| **Item 2** | **Unregistered Sales of Equity   Securities and Use of Proceeds.** |
|------------|--------------------------------------------------------------------|
|       |                                                               |
|       | Not applicable.                                                    |
|       |                                                               |
| **Item 3** | **Defaults   Upon Senior Securities.**                             |

          The Company signed a three-year note with Heller Healthcare Finance, Inc (“Heller”) and GE Healthcare Financial Services, Inc., as successor-in-interest to Heller (collectively “GE”) on August 30, 2004 (the “GE Note”). The GE Note was to expire on June 30, 2007.  The GE Note bore interest of 9%.  Covenants required the Company to maintain a minimum inventory balance of $1,500,000, minimum quarterly revenues of $1,000,000 and an annual net income provision.  For the year ended December 31, 2005 and any subsequent trailing twelve month periods, as measured on the last day of each calendar quarter, the Company’s earnings before interest, taxes, depreciation and amortization could not fall below $550,000. As of June 30, 2006, we were not in compliance with all covenants of our loan agreement. The Company had not met minimum quarterly revenue targets of$1,000,000, a rolling twelve-month $550,000 of EBIDTA and had not presented a budget for 2006.

          On June 7, 2006, the Company received a letter GE advised the Company that, if not waived by GE within ten days, the specified defaults would become “Events of Default” under the GE Note, which would allow GE to accelerate the amounts due under the GE Note.  The amount that would be due at that time was approximately $629,434, consisting of $476,077 of principal and $153,357 of fees.  GE also presented the Company a proposed Forbearance Agreement pursuant to which GE would forbear from exercising its rights and remedies under the GE Note with respect to the specified defaults until the earlier of (i) June 30, 2006, or (ii) the occurrence or existence of Events of Default under the GE Note other than the specified defaults.  Under that agreement, the Company would be required to pay immediately a fee of $10,000, and an additional $10,000 would be added to the indebtedness underthe GE Note.  However, on June 13, 2006, GE verbally agreed to waive the defaults without any additional charge to the Company and to extend until July 31, 2006, the date on which the specified defaults will become “Events of Default” under the GE Note.  The Company agreed to the terms of the waiver letter and pursued alternative financing arrangements during this waiver period.

          The Company and its subsidiary, LaserSight Technologies, Inc., (together, the “Borrowers”) entered into a Loan Agreement (the “NIIC Loan Agreement”) with New Industries Investment Consultants (HK) Ltd. (the “Lender”), an affiliate of the Company, dated as of July 26, 2006.  The Lender advanced funds in the amount of $750,000.00 to the Company on that date.  The purpose of the loan transaction was to allow the Company to pay in full its obligations to GE under the GE Note. The NIIC Loan Agreement enabled the Company to meet the GE deadline and avoid paying any additional fees. On July 27, 2006 the Company paid off the GE Note balance in full, with a cash payment of $575,561.

          The NIIC Loan Agreement provides for a loan to the Company (the “Loan”) in the maximum principal amount of $3,000,000, with an initial disbursement to the Company of $750,000.  Interest of nine percent (9%) per annum will accrue on the unpaid balance of the Loan, and such interest and the entire balance of principal, fees, costs and expenses shall be due and payable on June 30, 2007 (the “Maturity Date”).  The Loan may be prepaid, in full or in part, without penalty.  The Company agreed to pay a fee to the Lender of $15,000, as well as the Lender’s reasonable transaction costs related to the Loan, all of which will be due on the Maturity Date.  If not paid by the Maturity Date, the unpaid balance of the Loan will bear interest at the rate of twelve percent (12%) per annum.

Page 22

----

          Other terms and conditions of the Loan are nearly identical to the terms and conditions set forth in the Promissory Note and Security Agreement dated December 1, 2003, and the Restated Promissory Note dated August 31, 2004, made by the Borrowers in favor of the Lender (the “Prior Loan Documents”).  Such terms and conditions from the Prior Loan Documents were incorporated by reference into the NIIC Loan Agreement, to the extent that such terms and conditions do not conflict with the terms and conditions specifically set forth in the NIIC Loan Agreement.  However, one significant difference is that the Loan is not convertible into shares of the common stock of the Company.

| **Item 4** | **Submission of Matters to a Vote of   Security Holders.** |
|------------|------------------------------------------------------------|
|       |                                                       |
|       | Not applicable.                                            |
|       |                                                       |
| **Item 5** | **Other   Information.**                                   |
|       |                                                       |
|       | Not applicable.                                            |
|       |                                                       |
| **Item 6** | **Exhibits.**                                              |

| **Exhibit   Number** |   | **Description**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|----------------------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                      |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 3.1                  |   | Certificate of Incorporation, as amended *(filed as   Exhibit 3.1 to the Company’s Form 10-Q filed on November 14, 2002*)*.                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|                 |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 3.2                  |   | Bylaws, as amended *(filed as Exhibit 3.2 to the   Company’s Form 10-Q/A filed on November 21, 2002*)*.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                 |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 3.3                  |   | Certificate of Amendment of Certificate of   Incorporation *(filed as Exhibit 10.11 to   the Company’s Form 10-KSB filed on March 23, 2005*)*.                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|                 |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 4.1                  |   | Rights Agreement, dated as of July 2, 1998, between   LaserSight Incorporated and American Stock Transfer & Trust Company, as   Rights Agent, which includes (i) as Exhibit A thereto the form of Certificate   of Designation of the Series E Junior Participating Preferred Stock, (ii) as   Exhibit B thereto the form of Right Certificate (separate certificates for   the Rights will not be issued until after the Distribution Date) and (iii) as   Exhibit C thereto the Summary of Stockholder Rights Agreement *(filed as   Exhibit 99.1 to the Company’s Form 8-K filed July 8, 1998*)*. |
|                 |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.1                 |   | Product Purchase Agreement dated February 2, 2004,   between LaserSight Technologies, Inc. and Shenzhen New Industries Medical   Development Co., Ltd. *(filed as Exhibit 99.8 to the Company’s Form 8-K/A   filed on May 4, 2004*)*.                                                                                                                                                                                                                                                                                                                                                                    |
|                 |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.2                 |   | Distribution Agreement dated August 15, 2002,   between LaserSight Technologies, Inc. and Shenzhen New Industries Medical   Development Co., Ltd. *(filed as Exhibit 99.5 to the Company’s Form 8-K   filed on August 30, 2002*)***.                                                                                                                                                                                                                                                                                                                                                                     |

Page 23

----

| 10.3   |   | Amendment No. 2 to Loan and Security Agreement dated   as of August 15, 2002, among LaserSight Incorporated and subsidiaries and   Heller Healthcare Finance, Inc. *(filed as Exhibit 10.1 to the Company’s Form 10-Q   filed on November 14, 2002*)*.                                                                                                                |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                                                                                                                                                                                                                                       |
| 10.4   |   | Extension to Loan and Security Agreement dated as of   March 12, 2003, among LaserSight Incorporated and subsidiaries and Heller   Healthcare Finance, Inc. *(filed as Exhibit 10.40 to the Company’s Form 10-K   filed on March 31, 2003*)*.                                                                                                                         |
|   |   |                                                                                                                                                                                                                                                                                                                                                                       |
| 10.5   |   | Amendment No. 3 to Loan and Security Agreement dated   as of March 31, 2003 among LaserSight Incorporated and subsidiaries and   Heller Healthcare Finance, Inc. *(filed as Exhibit 10.41 to the Company’s Form 10-K   filed on March 31, 2003*)*.                                                                                                                    |
|   |   |                                                                                                                                                                                                                                                                                                                                                                       |
| 10.6   |   | Amendment No. 4 to Loan and Security Agreement and   Limited Waiver dated as of June 30, 2004, among LaserSight Incorporated and   subsidiaries and General Electric Capital Corporation as successor to GEHFS   Holdings, Inc., formerly known as Heller Healthcare Finance, Inc. *(filed as   Exhibit 10.8 to the Company’s Form 10-KSB filed on March 23, 2005*)*. |
|   |   |                                                                                                                                                                                                                                                                                                                                                                       |
| 10.7   |   | Amended and Restated Registration Rights Agreement   dated June 30, 2004, between LaserSight Incorporated and General Electric   Capital Corporation as successor to GEHFS Holdings, Inc., formerly known as   Heller Healthcare Finance, Inc. *(filed as Exhibit 10.9 to the Company’s Form 10-KSB   filed on March 23, 2005*)*.                                     |
|   |   |                                                                                                                                                                                                                                                                                                                                                                       |
| 10.8   |   | Restated Promissory note for $1,000,000, effective   June 30, 2004, made in favor of New Industries Investment Consultants (HK)   Ltd. by LaserSight Incorporated and its subsidiary, LaserSight Technologies,   Inc. *(filed   as Exhibit 10.10 to the Company’s Form 10-KSB filed on March 23, 2005*)*.                                                             |
|   |   |                                                                                                                                                                                                                                                                                                                                                                       |
| 10.9   |   | Non-Exclusive License Agreement between the Company   and WaveLight Laser Technologie AG, dated February 24, 2005, and effective   March 3, 2005 (*filed as Exhibit 10.1 to   the Company’s Form 10-QSB filed on April 25, 2005*)*.                                                                                                                                   |
|   |   |                                                                                                                                                                                                                                                                                                                                                                       |
| 10.10  |   | Amendment No. 1 to Third Amended and Restated   Secured Term Note, dated May 23, 2005, among LaserSight Incorporated and   subsidiaries and General Electric Capital Corporation *(filed as Exhibit 10.2 to the Company’s Form 10-QSB filed on August 5,   2005*)*.                                                                                                   |
|   |   |                                                                                                                                                                                                                                                                                                                                                                       |
| 10.11  |   | Amendment No. 1 to Restated Promissory Note, dated   February 15, 2006, between LaserSight Incorporated and New Industries   Investment Consultants (HK) Ltd. *(filed as   Exhibit 10.13 to the Company’s Form 10-KSB filed on March 31, 2006*)*.                                                                                                                     |
|   |   |                                                                                                                                                                                                                                                                                                                                                                       |
| 10.12  |   | Loan Agreement and Promissory Note, dated July 26,   2006, between LaserSight Incorporated and New Industries Investment   Consultants (HK) Ltd. *(filed   herewith)*.                                                                                                                                                                                                     |
|   |   |                                                                                                                                                                                                                                                                                                                                                                       |
| 11     |   | Statement of Computation of Loss Per Share *(included   in Financial Statements in Part I, Item 1, of this report)*.                                                                                                                                                                                                                                                       |

Page 24

----

| 31.1   |   | Certifications of Chief Executive Officer pursuant   to Rule 13a-14(a) |
|--------|--------|------------------------------------------------------------------------|
|   |   |                                                                   |
| 31.2   |   | Certifications of Chief Financial Officer pursuant   to Rule 13a-14(a) |
|   |   |                                                                   |
| 32.1   |   | Certifications of Chief Executive Officer pursuant   to Section 1350   |
|   |   |                                                                   |
| 32.2   |   | Certifications of Chief Financial Officer pursuant   to Section 1350   |

|        |
|--------|
|   |   |
| *      | Incorporated herein by reference.File No.0-19671. |
|   |   |
| **     | Confidential treatment has been granted for portions of this document. The redacted material has been filed separately with the commission. |

Page 25

----

SIGNATURES

          In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

|                   | **LaserSight   Incorporated** |
|------------------------|-------------------------------|
|                   |                          |   |
| Dated: August 14, 2006 | By:                           | /s/ Danghui (“David”) Liu |
|                   |                          |  |
|                   |                          | Danghui (“David”) Liu, President, |
|                   |                          | Chief Executive Officer and Director |
|                   |                          |   |
| Dated: August 14, 2006 | By:                           | /s/ Zhaokai Tang |
|                   |                          |  |
|                   |                          | Zhaokai Tang, |
|                   |                          | Interim Chief Financial Officer |

Page 26

----